Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Personalis, Tempus Enter Strategic Collaboration To Advance Cancer Testing

Author: Benzinga Newsdesk | November 28, 2023 05:28pm

As a part of the deal, Tempus will provide up to $12 million to Personalis as certain milestones are met, to help fund clinical evidence development for NeXT Personal Dx. Personalis wil compensate Tempus for the fair market value of sales, marketing, order requisition and results delivery services and provide warrants to Tempus to purchase up to approximately 9.2 million shares of Personalis' common stock over the next 24 months

Posted In: PSNL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist